# Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece

> **NCT05915182** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 212 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive (COPD)

## Interventions

- **COMBINATION_PRODUCT:** Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler

## Key facts

- **NCT ID:** NCT05915182
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-21
- **Primary completion:** 2025-03-28
- **Final completion:** 2025-03-28
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05915182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05915182, "Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05915182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*